1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Drugs In Development, 2022, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Gastric Ulcers - Overview
- Gastric Ulcers - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gastric Ulcers - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastric Ulcers - Companies Involved in Therapeutics Development
- Gastric Ulcers - Drug Profiles
- Gastric Ulcers - Dormant Projects
- Gastric Ulcers - Discontinued Products
- Gastric Ulcers - Product Development Milestones
- Featured News & Press Releases
- Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
- Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
- Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
- Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
- Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
- Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
- Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court
- Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
- Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals
- Oct 23, 2001: Prilosec US litigation
- May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec
- May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent
- Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement
- Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada
- Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Gastric Ulcers, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Gastric Ulcers - Pipeline by Axsome Therapeutics Inc, 2022
- Gastric Ulcers - Pipeline by Daewoong Co Ltd, 2022
- Gastric Ulcers - Pipeline by FortuneRock (China) Ltd, 2022
- Gastric Ulcers - Pipeline by Hunan Sailong Pharmaceutical Co Ltd, 2022
- Gastric Ulcers - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022
- Gastric Ulcers - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
- Gastric Ulcers - Pipeline by Korea Pharma Co Ltd, 2022
- Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2022
- Gastric Ulcers - Pipeline by PharmaKing Co Ltd, 2022
- Gastric Ulcers - Pipeline by RaQualia Pharma Inc, 2022
- Gastric Ulcers - Pipeline by Xiamen Encheng Pharmaceutical Co Ltd, 2022
- Gastric Ulcers - Pipeline by XuanZhu Biological Technology Co Ltd, 2022
- Gastric Ulcers - Dormant Projects, 2022
- Gastric Ulcers - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Gastric Ulcers, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Axsome Therapeutics Inc
- Daewoong Co Ltd
- FortuneRock (China) Ltd
- Hunan Sailong Pharmaceutical Co Ltd
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Korea Pharma Co Ltd
- Kukje Pharmaceutical Industry Co Ltd
- PharmaKing Co Ltd
- RaQualia Pharma Inc
- Xiamen Encheng Pharmaceutical Co Ltd
- XuanZhu Biological Technology Co Ltd
